相关实验视频
Updated: Sep 14, 2025
05:17
Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
Published on: April 18, 2025
357
在阿尔茨海默氏病的疾病阶段特定的缩标志物
Hannah Baumeister1, Helena M Gellersen1,2,3, Sarah E Polk1
1German Center for Neurodegenerative Diseases (DZNE), Magdeburg, Germany.
概括
结构性MRI可以使用特定标志物检测早期阿尔茨海默病 (AD) 缩. 将这些标志物与疾病阶段和预期使用量身定制,优化了阿尔茨海默病的诊断和预后价值.
科学领域:
- 神经成像是一种神经成像.
- 神经学 神经学
- 阿尔茨海默氏症疾病研究研究
背景情况:
- 结构性MRI在早期阿尔茨海默病 (AD) 诊断,预后和监测方面具有有限的实用性.
- 确定最佳缩标志物对于增强MRI在AD评估中的作用至关重要.
研究的目的:
- 为在阿尔茨海默病中不同用途确定最佳的结构性MRI缩标志物.
- 评估亚区域性缩标记在检测早期AD变化的有用性.
主要方法:
- 包括363名老年人:认知不受损 (粉胺-β阴性/阳性) 和粉胺-β阳性,主观认知衰退,轻度认知障碍或AD痴呆症.
- 每年进行MRI和神经心理评估,长达3年.
主要成果:
- 在临床前的AD中观察到加速的中间叶亚区域缩.
- 明显的海马体和形缩特征标志着症状性AD阶段.
- 缩和认知之间的关系因疾病阶段和预期用途而异.
结论:
- 亚区域性缩标志物可以检测临床前阿尔茨海默病的持续缩.
- 在临床前阿尔茨海默病的主观认知衰退与可测量的缩相关.
- 最佳的缩标志物必须根据特定的疾病阶段和预期的应用而定制.
相关概念视频
01:26Alzheimer's Disease: Overview
669
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
669
01:22Alzheimer's Disease: Treatment
262
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
262